Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study

医学 放射外科 临床终点 危险系数 观察研究 神经认知 递归分区 放射科 脑转移 放射治疗 核医学 内科学 临床试验 转移 癌症 置信区间 认知 精神科
作者
Masaaki Yamamoto,Toru Serizawa,Takashi Shuto,Atsuya Akabane,Yoshinori Higuchi,Jun Kawagishi,Kazuhiro Yamanaka,Yasunori Sato,Hidefumi Jokura,Shoji Yomo,Osamu Nagano,Hiroyuki Kenai,Akihito Moriki,Satoshi Suzuki,Yoshihisa Kida,Yoshiyasu Iwai,Motohiro Hayashi,Hiroaki Onishi,Masazumi Gondo,Mitsuya Sato
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:15 (4): 387-395 被引量:1442
标识
DOI:10.1016/s1470-2045(14)70061-0
摘要

Background We aimed to examine whether stereotactic radiosurgery without whole-brain radiotherapy (WBRT) as the initial treatment for patients with five to ten brain metastases is non-inferior to that for patients with two to four brain metastases in terms of overall survival. Methods This prospective observational study enrolled patients with one to ten newly diagnosed brain metastases (largest tumour <10 mL in volume and <3 cm in longest diameter; total cumulative volume ≤15 mL) and a Karnofsky performance status score of 70 or higher from 23 facilities in Japan. Standard stereotactic radiosurgery procedures were used in all patients; tumour volumes smaller than 4 mL were irradiated with 22 Gy at the lesion periphery and those that were 4–10 mL with 20 Gy. The primary endpoint was overall survival, for which the non-inferiority margin for the comparison of outcomes in patients with two to four brain metastases with those of patients with five to ten brain metastases was set as the value of the upper 95% CI for a hazard ratio (HR) of 1·30, and all data were analysed by intention to treat. The study was finalised on Dec 31, 2012, for analysis of the primary endpoint; however, monitoring of stereotactic radiosurgery-induced complications and neurocognitive function assessment will continue for the censored subset until the end of 2014. This study is registered with the University Medical Information Network Clinical Trial Registry, number 000001812. Findings We enrolled 1194 eligible patients between March 1, 2009, and Feb 15, 2012. Median overall survival after stereotactic radiosurgery was 13·9 months [95% CI 12·0–15·6] in the 455 patients with one tumour, 10·8 months [9·4–12·4] in the 531 patients with two to four tumours, and 10·8 months [9·1–12·7] in the 208 patients with five to ten tumours. Overall survival did not differ between the patients with two to four tumours and those with five to ten (HR 0·97, 95% CI 0·81–1·18 [less than non-inferiority margin], p=0·78; pnon-inferiority<0·0001). Stereotactic radiosurgery-induced adverse events occurred in 101 (8%) patients; nine (2%) patients with one tumour had one or more grade 3–4 event compared with 13 (2%) patients with two to four tumours and six (3%) patients with five to ten tumours. The proportion of patients who had one or more treatment-related adverse event of any grade did not differ significantly between the two groups of patients with multiple tumours (50 [9%] patients with two to four tumours vs 18 [9%] with five to ten; p=0·89). Four patients died, mainly of complications relating to stereotactic radiosurgery (two with one tumour and one each in the other two groups). Interpretation Our results suggest that stereotactic radiosurgery without WBRT in patients with five to ten brain metastases is non-inferior to that in patients with two to four brain metastases. Considering the minimal invasiveness of stereotactic radiosurgery and the fewer side-effects than with WBRT, stereotactic radiosurgery might be a suitable alternative for patients with up to ten brain metastases. Funding Japan Brain Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
牧木完成签到,获得积分10
刚刚
影逐光发布了新的文献求助10
刚刚
1秒前
传奇3的应助被hahage采纳,获得50
1秒前
精明梦柏完成签到,获得积分10
1秒前
1秒前
核桃发布了新的文献求助10
1秒前
勇猛的小qin完成签到 ,获得积分10
1秒前
冷酷的问梅完成签到,获得积分10
2秒前
科研通AI2S的应助被curry采纳,获得10
2秒前
自信谷冬发布了新的文献求助10
2秒前
宁灭龙发布了新的文献求助10
2秒前
3秒前
明理鸿完成签到,获得积分10
3秒前
如何让人发布了新的文献求助10
3秒前
4秒前
4秒前
顾矜的应助被wang采纳,获得30
4秒前
4秒前
4秒前
5秒前
mm完成签到,获得积分10
5秒前
6秒前
jiangjiang完成签到,获得积分10
6秒前
yyyyyy完成签到,获得积分10
6秒前
6秒前
科研通AI2S的应助被牧木采纳,获得10
6秒前
lz完成签到,获得积分10
6秒前
WYH发布了新的文献求助10
6秒前
田好好发布了新的文献求助10
7秒前
123完成签到 ,获得积分10
7秒前
123发布了新的文献求助10
7秒前
小蘑菇的应助被谨慎的秋烟采纳,获得10
7秒前
alandan发布了新的文献求助10
7秒前
7秒前
1cc完成签到,获得积分10
7秒前
8秒前
zed320完成签到,获得积分10
8秒前
8秒前
XxX发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155737
求助须知:如何正确求助?哪些是违规求助? 9552018
关于积分的说明 21707687
捐赠科研通 7744923
什么是DOI,文献DOI怎么找? 3426177
关于科研通互助平台的介绍 2551229
邀请新用户注册赠送积分活动 2469949